198 related articles for article (PubMed ID: 37955063)
1. Antibody drug conjugates for glioblastoma: current progress towards clinical use.
Gan HK; Parakh S; Osellame LD; Cher L; Uccellini A; Hafeez U; Menon S; Scott AM
Expert Opin Biol Ther; 2023; 23(11):1089-1102. PubMed ID: 37955063
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
[TBL] [Abstract][Full Text] [Related]
3. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.
Anami Y; Otani Y; Xiong W; Ha SYY; Yamaguchi A; Rivera-Caraballo KA; Zhang N; An Z; Kaur B; Tsuchikama K
Cell Rep; 2022 May; 39(8):110839. PubMed ID: 35613589
[TBL] [Abstract][Full Text] [Related]
4. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
Mair MJ; Bartsch R; Le Rhun E; Berghoff AS; Brastianos PK; Cortes J; Gan HK; Lin NU; Lassman AB; Wen PY; Weller M; van den Bent M; Preusser M
Nat Rev Clin Oncol; 2023 Jun; 20(6):372-389. PubMed ID: 37085569
[TBL] [Abstract][Full Text] [Related]
5. Toxic warhead-armed antibody for targeted treatment of glioblastoma.
Xi J; Liu K; Peng Z; Dai X; Wang Y; Cai C; Yang D; Yan C; Li X
Crit Rev Oncol Hematol; 2024 Jan; 193():104205. PubMed ID: 38036153
[TBL] [Abstract][Full Text] [Related]
6. Investigational antibody drug conjugates for solid tumors.
Sapra P; Hooper AT; O'Donnell CJ; Gerber HP
Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
Chu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
[TBL] [Abstract][Full Text] [Related]
8. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
9. Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?
Parakh S; Nicolazzo J; Scott AM; Gan HK
Front Oncol; 2021; 11():718590. PubMed ID: 34926242
[TBL] [Abstract][Full Text] [Related]
10. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
14. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
15. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
[TBL] [Abstract][Full Text] [Related]
16. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):741-762. PubMed ID: 37460440
[TBL] [Abstract][Full Text] [Related]
17. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
19. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy.
Deonarain MP; Yahioglu G
Expert Opin Drug Discov; 2021 Jun; 16(6):613-624. PubMed ID: 33275475
[No Abstract] [Full Text] [Related]
20. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
